Skip to content
Back to meeting Original
Grupo GETNE· @GrupoGetne · X·· 3 days agoScore70

cabozantinib

Body

#ESMO26 🇪🇸 🧬 GETNE-CABOTHYROID | Fase II

presentado por @JHernando3

👥 41 pacientes | Cáncer de tiroides refractario a radioyodo
💊 Cabozantinib
🎯 ORR 25,6%
📈 SLP 16,1 meses
⏳ DoR 18,4 meses
🧬 Metilación de cfDNA: potenciales biomarcadores predictivos.

🔬 ¡Seguimos impulsando la investigación desde @GrupoGetne

332 views · 11 likes · 2 reposts · 0 replies

Source: Grupo GETNE · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.